Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ICER On Asthma Biologics: 50%-79% Price Discounts Needed To Meet Value Assessment Metrics

Nov 15 2018

• By Jessica Merrill

scales measuring price versus value, equal rate

Related Content

Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics

Oct 21 2018

CVS Launching Program To Exclude New Drugs Deemed Not Cost Effective

Aug 09 2018

Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence

May 23 2018

Related Companies

Roche Holding AG

GSK plc

Teva Pharmaceutical Industries Ltd.

AstraZeneca PLC

Regeneron Pharmaceuticals, Inc.

Sanofi

CVS Health Corp.

Additional Topics

Pricing Strategies Cost Effectiveness Commercial Respiratory BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window